

Supplement

Table 4S. Characteristics of Patients with Diabetes Mellitus at Baseline Randomized to Evacetrapib or Placebo.

	Evacetrapib (N = 4,127)	Placebo (N = 4,109)	P-value
Mean Age in Years \pm SD	65.3 \pm 8.7	65.7 \pm 8.7	0.08
Male sex (%)	76	76	0.85
Race – (%)			0.94
White	78	79	
Black	2.9	3.0	
Asian	13	13	
Other	5.5	5.2	
Mean Body Mass Index \pm SD	31.2 \pm 6.0	31.1 \pm 5.8	0.45
Index diagnosis (%)			
Recent ACS 30-365 days	16	16	0.81
Cerebrovascular disease	21	21	0.85
Peripheral arterial disease	17	16	0.36
CAD	93	93	0.85
Cardiovascular risk factors (%)			
Hypertension	91	92	0.29
Current smoker	15	14	0.61
Prior myocardial infarction	60	60	0.76
Prior PCI	70	71	0.30
Prior CABG	34	32	0.16
Prior heart failure	15	15	0.90
COPD	11	10	0.17
Renal Impairment	11	10	0.41
Lipids – mg/dl			
Mean LDL cholesterol	80 \pm 28	80 \pm 27	0.11
Mean HDL cholesterol	44 \pm 11	44 \pm 11	0.57
Median Triglyceride (IQR)	137 (100, 187)	136 (99, 186)	0.31
Mean Apolipoprotein A1	137 \pm 25	137 \pm 25	0.98
Mean Apolipoprotein B	79 \pm 22	78 \pm 21	0.03
Median lipoprotein (a) (IQR)	27 (10, 98)	28 (11, 100)	0.53
Median Hs CRP (IQR) (mg/l)	1.6 (0.77, 3.5)	1.5 (0.74, 3.4)	0.41
Medications – (%)			
Any statin	96	96	0.35
High intensity statin	43	43	0.69
ACEi/ARB	81	80	0.73
Aspirin	84	83	0.77

Table 5S. Characteristics of Patients without Diabetes Mellitus at Baseline Randomized to Evacetrapib or Placebo.

	Evacetrapib (N = 1,911)	Placebo (N = 1,945)	P-value
Mean Age in Years ± SD	62.2 ± 10.4	62.2 ± 10.5	0.92
Male sex (%)	78	79	0.80
Race – (%)			0.20
White	91	91	
Black	1.1	1.7	
Asian	5.2	4.9	
Other	3.1	2.4	
Mean Body Mass Index ± SD	28.3 ± 4.6	28.3 ± 4.8	0.79
Index diagnosis (%)			
Recent ACS 30-365 days	61	62	0.30
Cerebrovascular disease	25	25	0.96
Peripheral arterial disease	27	24	0.08
CAD	83	83	0.60
Cardiovascular risk factors (%)			
Hypertension	78	78	0.77
Current smoker	21	19	0.12
Prior myocardial infarction	83	83	0.93
Prior PCI	73	74	0.30
Prior CABG	19	21	0.39
Prior heart failure	11	11	0.68
COPD	10	10	0.72
Renal Impairment	5	5	0.69
Lipids – mg/dl			
Mean LDL cholesterol	84 ± 29	84 ± 30	0.60
Mean HDL cholesterol	48 ± 12	48 ± 12	0.38
Median Triglyceride (IQR)	114 (87, 159)	113 (85, 159)	0.88
Mean Apolipoprotein A1	143 ± 26	142 ± 26	0.33
Mean Apolipoprotein B	78 ± 23	79 ± 23	0.46
Median lipoprotein (a) (IQR)	34 (14, 128)	31 (11, 121)	0.57
Median Hs CRP (IQR) (mg/l)	1.5 (0.69, 3.0)	1.4 (0.73, 3.0)	0.88
Medications – (%)			
Any statin	97	97	0.63
High intensity statin	54	55	0.55
ACEi/ARB	72	73	0.53
Aspirin	82	80	0.17

Table 6S. Multivariable model for the primary composite endpoint by treatment assigned amongst patients with diabetes mellitus.

Variable	HR	95% CI	P-Value
Treatment with Evacetrapib	0.95	(0.84, 1.06)	0.35
Age*	1.05	(0.98, 1.13)	0.16
Male	1.03	(0.90, 1.18)	0.67
Coronary Artery Disease	1.71	(1.29, 2.26)	< 0.001
Cerebral Vascular Disease	1.43	(1.25, 1.63)	< 0.001
Peripheral Artery Disease	1.33	(1.15, 1.55)	< 0.001
Renal Impairment	1.25	(1.06, 1.48)	0.010
Hypertension	1.47	(1.13, 1.91)	0.004
Heart Failure	1.55	(1.35, 1.78)	< 0.001
Smoker	1.18	(1.00, 1.39)	0.05
LDL*	1.03	(1.01, 1.05)	0.002

* Hazard ratio per 10 units

Table 7S. Multivariable model for the primary composite endpoint by treatment assigned amongst patients without diabetes mellitus.

Variable	HR	95% CI	P-Value
Treatment with Evacetrapib	1.14	(0.93, 1.40)	0.20
Age*	1.08	(0.97, 1.21)	0.15
Male	0.89	(0.70, 1.13)	0.32
Coronary Artery Disease	2.56	(1.79, 3.67)	< 0.001
Cerebral Vascular Disease	1.28	(1.01, 1.62)	0.04
Peripheral Artery Disease	1.33	(1.05, 1.68)	0.02
Renal Impairment	0.99	(0.64, 1.52)	0.95
Hypertension	1.54	(1.15, 2.07)	0.004
Heart Failure	1.27	(0.95, 1.68)	0.10
Smoker	0.93	(0.71, 1.22)	0.59
LDL*	1.05	(1.02, 1.08)	0.003

* Hazard ratio per 10 units